This letter provides a critical perspective on the recently published article "Haemolysis is a concerning bias in some ozone therapy approaches." While acknowledging the importance of addressing potential haemolysis in oxygen-ozone therapy, we highlight key concerns regarding the lack of direct experimental evidence supporting the claimed association between glass containers and increased haemolysis. Additionally, we emphasize the reliance on in vitro studies without corroborating clinical data, which limits the generalizability of the conclusions. We also discuss the transparency issues surrounding the SIOOT guidelines, which are frequently referenced but not publicly accessible, restricting independent validation. Finally, we challenge the assertion that haemolysis is a major side effect of systemic oxygen-ozone therapy, noting that the current literature does not substantiate this claim. We advocate for a more rigorous, evidence-based approach to ensure transparency, completeness of data, and validation of scientific assertions, ultimately contributing to the safe and effective application of oxygen-ozone therapy.